Emerging Diagnostic Technologies for Use in Psychiatric Indications

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• The Importance of Diagnostic Technologies for Psychiatric Indications
• Value of Biomarker-Based Diagnostics for Psychiatric Diseases
• Diffi culties in Diagnosing Psychiatric Illness
  • Presentation of Prodromal Symptoms Can Be Slow and Variable
  • Several Disorders May Have Similar Symptomatology
  • Patients with Multiple Mental Illnesses May be Diffi cult to Diagnose
  • Some Mental Illnesses May Be Broad Categories of Diseases
• Challenges in Determining Optimal Treatment
• Current Medical Practice for Psychiatric Indications
• Current and Emerging Diagnostic Technologies for Psychiatric Indications
  • Electroencephalography
    • Aspect Medical Systems
    • CNS Response
    • Memory Pharmaceuticals/Roche and Envivo Pharmaceuticals
  • Molecular Diagnostics
    • Clinical Data
    • CombiMatrix
    • Curidium Medica
    • Roche/Affymetrix
    • Vanda Pharmaceuticals
  • Diagnostic Imaging
• Outlook
• Appendix A. Thought Leaders Consulted for This Report
• Appendix B. Bibliography

Expert Commentaries

• What Do Thought Leaders Say About the Potential Use of Biomarkers in Psychiatric Diagnosis and Treatment?
  • Carlos Dedesma, Analyst, Decision Resources, Inc
• The Potential for rEEG to Create Win-Win Situations for Stakeholders
  • Leonard Brandt, CEO, CNS Response
• Disentangling Patient Populations to Develop More-Effective Drug Therapies
  • Anne T. Bruinvels, Ph.D., Founder and CSO, Curidium Medica

Sidebar

• 510(k) vs. PMA

Tables

• 1. Diagnostic Collaborations in Psychiatric Indications, 2004-March 2008
• 2. Roche' s AmpliChip CYP450 Test: Summary of Attributes
• 3. Major Opportunities and Challenges for Psychiatric Diagnostics

• A. Drug Development Benefi ts by Development Phase

Figures

• 1. How Diagnostic Technologies Can Increase Treatment Effi cacy
• 2. Referenced-EEG Sample Report to Physicians from CNS Response

• A. Medications Predicted by rEEG
• B. Schematic Overview of the Studies Undertaken by Curidium to Identify a Blood Diagnostic Tool to Select Schizophrenia and Bipolar Disorder Patient Subgroups in the Clinic